Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

NKT Therapeutics’ Sickle Cell Disease Drug Receives FDA Fast Track

October 2, 2014 2:42 pm | News | Comments

NKT Therapeutics announced that FDA has granted Fast Track designation to NKTT120, the company’s lead therapeutic being developed for the treatment of sickle cell disease. Read more...

TOPICS:

Lilly Discontinues Development of Lupus Drug

October 2, 2014 2:33 pm | News | Comments

Eli Lilly and Company announced it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. Read more...

TOPICS:

Experimental Ebola Vaccine Processed in Maryland

October 2, 2014 2:22 pm | News | Comments

The National Institute of Allergy and Infectious Diseases said an experimental Ebola vaccine is being processed at a facility in Frederick. The Frederick News-Post reported that the vaccine is a joint project between the federal agency and GlaxoSmithKline. Read more...

TOPICS:
Advertisement

Amgen Announces Positive Data for Cholesterol-Lowering Medication

October 2, 2014 2:12 pm | News | Comments

Amgen announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH). Read more...

TOPICS:

Takeda Announces Phase 3 Data for UC, Crohn's Drug

October 2, 2014 10:29 am | News | Comments

Takeda announced that new data from GEMINI LTS, a Phase 3, ongoing, open-label extension study of Entyvio (vedolizumab) for the treatment of adults with moderately to severely active UC and CD will be presented as oral presentations during the 21st United European Gastroenterology Week in Vienna, Austria. Read more...

TOPICS:

Japan Starts World-First Stem Cell Trial, Plans More

October 2, 2014 10:20 am | by Cynthia Fox, Science Editor | Articles | Comments

The first patient has been treated, by Japan’s Riken Institute, in the world’s first clinical study of stem cells made from ordinary mature cells. The cells were retinal pigment epithelial (RPE) cells, but they began as a macular-degeneration patient’s skin cells.

TOPICS:

High-Cholesterol Drug Data Lifts Esperion

October 2, 2014 10:13 am | News | Comments

Shares of Esperion Therapeutics surged in aftermarket trading after the company reported positive clinical trial results for its experimental high-cholesterol drug ETC-1002. Read more...                   

TOPICS:

Discovery Helps to Spot What Makes a Good Drug

October 2, 2014 10:03 am | News | Comments

A new test developed by researchers from The University of Manchester could revolutionize the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. Read more...

TOPICS:
Advertisement

New Type of Clinic Eyed to Help Stop Ebola

October 2, 2014 9:45 am | by Maria Cheng and Sarah Dilorenzo | News | Comments

Britain and Sierra Leone are appealing for more help to slow the biggest ever Ebola outbreak - and are proposing a new type of clinic to do that. At a London conference, officials are expected to announce plans to build up to 1,000 makeshift Ebola clinics in Sierra Leone.  Read more...

TOPICS:

Drugmaker Submits Harder-to-Abuse Zohydro to FDA

October 2, 2014 9:33 am | by Matthew Perrone, AP Health Writer | News | Comments

The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring. Read more...          

TOPICS:

New Drug-Delivery Capsule May Replace Injections

October 1, 2014 4:15 pm | News | Comments

Researchers have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. Read more...                      

TOPICS:

‘Stealth’ Nanoparticles Could Improve Cancer Vaccines

October 1, 2014 4:05 pm | News | Comments

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. Read more...

TOPICS:

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

October 1, 2014 3:59 pm | News | Comments

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to new research. Read more...

TOPICS:

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:52 pm | News | Comments

Drugmaker Merck said that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Read more...     

TOPICS:

Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Data

October 1, 2014 3:45 pm | News | Comments

Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading